Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Jazz Pharma Plc (NQ: JAZZ ) 114.29 +0.42 (+0.37%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Jazz Pharma Plc < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court January 05, 2023 Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS Via Benzinga 2 Cannabis Stocks to Buy for the Long Haul December 31, 2022 Don't give up on this sector too quickly. Via The Motley Fool 2 Growth Stocks to Buy Heading Into 2023 December 30, 2022 These biotechs are far from having achieved their full potential. Via The Motley Fool 2 Top Biotech Stocks to Buy for the Long Haul December 25, 2022 These mid-cap biotechs are solid long-term choices. Via The Motley Fool Better Buy: Moderna vs Axsome December 22, 2022 Revenue prospects look promising for both of these biotech companies. Via The Motley Fool Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today December 21, 2022 U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation... Via Benzinga Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks December 21, 2022 Via Benzinga 6 Analysts Have This to Say About Jazz Pharmaceuticals December 09, 2022 Via Benzinga After Jumping 100%, Is Axsome a Buy Before 2023? December 16, 2022 Axsome's revenue story is just getting started. Via The Motley Fool Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday December 09, 2022 Wells Fargo raised Netflix, Inc. (NASDAQ: NFLX) price target from $300 to $400. Wells Fargo also upgraded the stock from Equal Weight to Overweight. Netflix shares rose 0.6% to close at $310.26 on... Via Benzinga What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals December 09, 2022 Via Benzinga 2 Unstoppable Growth Stocks to Buy in 2022 and Beyond December 08, 2022 These biotech players beat the bear market this year. Via The Motley Fool 3 Fierce Stocks That Are Screaming Buys in December December 07, 2022 Here are three winners in the making. Via The Motley Fool Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy December 05, 2022 Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) caregiver survey that showed a substantial proportion of caregivers... Via Benzinga Is Axsome Therapeutics Stock a Buy Now? November 11, 2022 The company seems to be coming into its own. Via The Motley Fool Biotech Space Offers Reward In 2023 Despite Economic Risks November 30, 2022 Despite the economic headwinds, the mid-to long-term outlook for the biotech space remains strong, and investors who are able to take advantage of undervalued biotech stocks may be well-positioned for... Via Talk Markets Struggling Axsome Stock Could Bounce Back on Drug Trial Success November 30, 2022 Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. Via MarketBeat Exposures Product Safety Q3 Proves To Be Another Tough Quarter For Cannabis November 28, 2022 It’s been a tough year for cannabis investors and Q3 offered little relief. Via Talk Markets Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling November 28, 2022 The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. Via Benzinga Want to Double Your Money? Buying These Stocks Could be a Genius Move November 28, 2022 These stocks are undervalued considering their long-term growth potential. Via The Motley Fool Prediction: This Growth Stock Could Double in 2023 November 24, 2022 The next year should be a busy one for this drugmaker. Via The Motley Fool Three CBD Stocks to Dominate a Budding Industry November 23, 2022 The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity. Via MarketBeat Topics Cannabis Exposures Cannabis Product Safety Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling November 21, 2022 Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent. Via Benzinga Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent November 21, 2022 Via Benzinga Got $500? 3 Growth Stocks to Buy That Could Double Your Money November 20, 2022 Innovative products and services could keep these companies growing. Via The Motley Fool 3 Top Cannabis Stocks to Buy in November November 20, 2022 These solid performers are managing to grow revenue in a difficult environment. Via The Motley Fool 2 Dirt Cheap Growth Stocks to Buy and Hold for Years November 18, 2022 In the long run, these stocks could deliver great returns. Via The Motley Fool What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals November 10, 2022 Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: Via Benzinga Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance November 10, 2022 Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance. Via Benzinga Why Axsome Therapeutics Stock Slipped Today November 07, 2022 Investors traded out of the company following the latest earnings release, but only to a modest degree. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.